Popular Articles
Teeth Whitening Products

Exenatide Once Weekly Provided Superior Glucose Control Compared To Lantus(R) In Head-to-Head DURATION-3 Study
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results from a study comparing subjects randomized to either exenatide once weekly or Lantus® (insulin glargine). Patients randomized to exenatide once weekly experienced a statistically superior reduction in A1C, a measure of average blood sugar over three months, of 1.5 percentage points from baseline, compared to a reduction of 1.3 percentage points for Lantus after completing 26 weeks of treatment. At the end of the study, patients treated with exenatide once weekly achieved a mean A1C of 6.8 percent compared with a mean A1C of 7.0 percent in those treated with Lantus. Treatment with exenatide once weekly also produced a statistically significant difference in weight, with a mean weight loss of 5.8 pounds at 26 weeks, compared with a mean weight gain of 3.1 pounds for Lantus, a difference of 8.9 pounds between the treatments.
generic viagra online
Expanded Testing Reveals 2000 Percent Increase In Number Of HIV-Positive Indian Children
"Expanded testing across India in the past three years shows a 2,000 percent jump in the number of HIV cases among children, [Ghulam Nabi Azad] the country"s health minister announced Wednesday," CNN reports. As of May 2009, reports found that nearly 53,000 children are living with HIV in India - up from 2,253 recorded cases in November 2006, Azad said during an address to the parliament (Singh, 7/29).
News of the day
1st Anticancer Drug For Animals Offers Human Treatment Possibilities
AB Science, a young Paris-based biotech company, announces the pan-European commercial launch of its Masivet veterinary anticancer drug in June 2009. Masivet was approved in November 2008 by the European Medicines Agency (EMEA) for the treatment of dogs with non-resectable grade 2 or 3 mast cell tumours. Masivet"s active pharmaceutical ingredient is masitinib, a tyrosine kinase inhibitor. Masitinib, discovered and developed by AB Science, belongs to a therapeutic class of drug known as targeted therapy that is revolutionising the treatment of cancer in humans.
Public Health

San Jose Mercury News Slams The Governor's Health Care Cuts

The San Jose Mercury News blasted the governor"s plan to gut health care funding for children and the poor. In an editorial published Sunday, the Merc said: ". . . the cuts the governor has proposed so far inflict far more damage than necessary, in part because they needlessly throw away federal dollars. He has better options. Schwarzenegger is suggesting California eliminate its Healthy Families program and enact a $750 million cut in Medi-Cal eligibility, both so pound-foolish that we can"t even call them penny-wise." The California Medical Association opposes the health care cuts and believes Medi-Cal savings could be found in other areas, such as modernizing and streamlining its overly burdensome Treatment Authorization Request (TAR) process. By requiring this paperwork, the state is inhibiting access to care and adding unnecessary costs and delays to the system. CMA will join Assemblymen Ted Lieu, D-Torrance, and Jim Beall, D-San Jose, on Wednesday in asking the Joint Legislative Audit Committee (JLAC) to order an audit of the TAR process. Dr. Ted Mazer, an ear, nose and throat physician from San Diego, will address the committee on CMA"s behalf and talk about how TARs and other program problems led him to quit taking Medi-Cal patients. JLAC"s hearing is scheduled to begin at 9 a.m. Holler if you"d like any background or have any questions! California Medical Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):